Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 7686 results

  1. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Advanced breast cancer: diagnosis and management (Partial update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 21 November 2024.

    NICE guideline
    In consultation

  3. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 19 December 2024

    Diagnostics guidance
    In development

  4. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  6. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  7. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  8. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  11. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  12. Intermittent urethral catheters for urinary management in adults : Late Stage Assessment

    In development [GID-HTE10049] Expected publication date: TBC

    Health technology evaluations
    In development

  13. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development [GID-TA10981] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  14. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  15. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development